BridgeBio Pharma (BBIO) Research & Development (2018 - 2026)
BridgeBio Pharma recorded quarterly Research & Development of $126.6 million in Q1 2026, up 8.78% quarter-over-quarter from $116.4 million in Q4 2025, and up 13.65% year-over-year from $111.4 million in Q1 2025.
BridgeBio Pharma's Research & Development history runs 9 years deep, the most recent figure standing at $126.6 million for Q1 2026.
- In Q1 2026, Research & Development rose 13.65% year-over-year to $126.6 million; the TTM figure through Mar 2026 stood at $467.2 million (down 2.05% YoY), while the FY2025 annual figure was $452.0 million, down 10.76% from the prior year.
- Research & Development came in at $126.6 million for Q1 2026 at BridgeBio Pharma, up from $116.4 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $141.0 million in Q1 2024 to a low of $90.9 million in Q4 2022.
- A 5-year average of $114.1 million and a median of $112.9 million in 2025 frame the typical range for Research & Development.
- Across the five-year window, Research & Development fell 25.61% in 2022 and surged 51.81% in 2024, its largest moves.
- BridgeBio Pharma's Research & Development stood at $90.9 million in 2022, then jumped by 43.26% to $130.2 million in 2023, then gained by 0.1% to $130.4 million in 2024, then fell by 10.69% to $116.4 million in 2025, then climbed by 8.78% to $126.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $126.6 million, $116.4 million, and $112.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | 126.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126.64 Mn |
| Dec 31, 2025 | 116.42 Mn |
| Sep 30, 2025 | 112.87 Mn |
| Jun 30, 2025 | 111.23 Mn |
| Mar 31, 2025 | 111.43 Mn |
| Dec 31, 2024 | 130.35 Mn |
| Sep 30, 2024 | 120.44 Mn |
| Jun 30, 2024 | 114.70 Mn |
| Mar 31, 2024 | 140.97 Mn |
| Dec 31, 2023 | 130.23 Mn |
| Sep 30, 2023 | 125.14 Mn |
| Jun 30, 2023 | 107.49 Mn |
| Mar 31, 2023 | 92.86 Mn |
| Dec 31, 2022 | 90.90 Mn |
| Sep 30, 2022 | 92.51 Mn |
| Jun 30, 2022 | 108.40 Mn |
| Mar 31, 2022 | 107.65 Mn |
| Dec 31, 2021 | 122.20 Mn |
| Sep 30, 2021 | 104.31 Mn |
| Jun 30, 2021 | 101.96 Mn |
| Mar 31, 2021 | 122.56 Mn |
| Dec 31, 2020 | 90.17 Mn |
| Sep 30, 2020 | 92.05 Mn |
| Jun 30, 2020 | 86.60 Mn |
| Mar 31, 2020 | 68.23 Mn |
| Dec 31, 2019 | 57.49 Mn |
| Sep 30, 2019 | 55.28 Mn |
| Jun 30, 2019 | 52.33 Mn |
| Mar 31, 2019 | 44.85 Mn |
| Dec 31, 2018 | 51.20 Mn |
| Sep 30, 2018 | 31.15 Mn |